Acquisition by Leonard Braden Michael of 102076 shares of OnKure Therapeutics, subject to Rule 16b-3

OKUR Stock   15.42  0.66  4.47%   
Slightly above 55% of OnKure Therapeutics,'s retail investors are presently thinking to get in. The analysis of overall sentiment of trading OnKure Therapeutics, stock suggests that some investors are interested at this time. OnKure Therapeutics,'s investing sentiment overview a quick insight into current market opportunities from investing in OnKure Therapeutics,. Many technical investors use OnKure Therapeutics, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by OnKure Therapeutics, Other: Former 10% Owner Of Rphm. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at news.google.com
Google News at Macroaxis
  
OnKure insider trading alert for acquisition of common stock by Leonard Braden Michael, Other: Former 10% Owner Of Rphm, on 7th of October 2024. This event was filed by OnKure Therapeutics, with SEC on 2024-10-07. Statement of changes in beneficial ownership - SEC Form 4

OnKure Therapeutics, Fundamental Analysis

We analyze OnKure Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OnKure Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OnKure Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

OnKure Therapeutics, is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

OnKure Therapeutics, Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OnKure Therapeutics, stock to make a market-neutral strategy. Peer analysis of OnKure Therapeutics, could also be used in its relative valuation, which is a method of valuing OnKure Therapeutics, by comparing valuation metrics with similar companies.

Additional Tools for OnKure Stock Analysis

When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.